Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid.
Welcome to the 21st edition of the Cancer Research Blog Carnival, the monthly blog carnival that discusses what’s new in cancer research and includes posts covering cancer biology, cancer genetics, cancer diagnostics and cancer therapeutics. Concomitant with this edition is the start of National Cancer Research Month.
In the digital age, these are the characteristics of new media: recent, relevant, reachable and reliable.
In 2007, the United States Congress declared May National Cancer Research Month. The American Association for Cancer Research (AACR) secured resolutions to raise awareness of the critical advances in cancer research made by its 27,000 members and cancer researchers worldwide, and its efforts to ensure a secure future for continued progress against a group of diseases which strike one in every two men and one in every three women.
Today, ten million cancer survivors are alive in America due to advances in cancer research . National Cancer Research Month reminds us that basic, clinical, epidemiological and behavioral research are essential to identifying causes and developing strategies for cancer prevention, diagnosis, treatment and cures.
With that, let’s find out more about what’s happening in cancer research this month.